{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bile+Duct+Cancer+Recurrent&page=2", "query": { "condition": "Bile Duct Cancer Recurrent", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bile+Duct+Cancer+Recurrent&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T17:23:30.584Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003867", "title": "Irinotecan and Capecitabine in Treating Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 30, "start_date": "1999-03", "completion_date": "2003-03", "has_results": false, "last_update_posted_date": "2018-09-10", "last_synced_at": "2026-06-25T17:23:30.584Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003867" }, { "nct_id": "NCT00031681", "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Carcinoma of the Appendix", "Estrogen Receptor-negative Breast Cancer", "Extensive Stage Small Cell Lung Cancer", "Gastrointestinal Stromal Tumor", "HER2-negative Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Ovarian Sarcoma", "Ovarian Stromal Cancer", "Progesterone Receptor-negative Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Cell Lung Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Small Intestine Adenocarcinoma", "Small Intestine Leiomyosarcoma", "Small Intestine Lymphoma", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Anal Cancer", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Gastric Cancer", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Triple-negative Breast Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "7-hydroxystaurosporine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-06-25T17:23:30.584Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031681" }, { "nct_id": "NCT04641871", "title": "Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Solid Tumor" ], "interventions": [ { "name": "Sym021", "type": "DRUG" }, { "name": "Sym022", "type": "DRUG" }, { "name": "Sym023", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2020-10-12", "completion_date": "2024-06-03", "has_results": false, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-06-25T17:23:30.584Z", "location_count": 12, "location_summary": "Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04641871" }, { "nct_id": "NCT02088775", "title": "PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Metastatic Extrahepatic Bile Duct Cancer", "Recurrent Adult Primary Liver Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Stage D Adult Primary Liver Cancer (BCLC)", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "PET scan", "type": "PROCEDURE" }, { "name": "CT Scan", "type": "PROCEDURE" }, { "name": "hepatic artery embolization", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2014-02", "completion_date": "2021-07-30", "has_results": false, "last_update_posted_date": "2024-01-16", "last_synced_at": "2026-06-25T17:23:30.584Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02088775" }, { "nct_id": "NCT00009893", "title": "Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Liver Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 42, "start_date": "2001-05", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2016-12-07", "last_synced_at": "2026-06-25T17:23:30.584Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00009893" }, { "nct_id": "NCT00005842", "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "tipifarnib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2000-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-06-25T17:23:30.584Z", "location_count": 2, "location_summary": "Fort Sam Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Fort Sam Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005842" }, { "nct_id": "NCT02495896", "title": "Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Metastatic Pancreatic Adenocarcinoma", "Non-Resectable Cholangiocarcinoma", "Pancreatic Adenocarcinoma", "Recurrent Gallbladder Carcinoma", "Recurrent Non-Small Cell Lung Carcinoma", "Stage III Pancreatic Cancer", "Stage IIIA Gallbladder Cancer", "Stage IIIA Non-Small Cell Lung Cancer", "Stage IIIB Gallbladder Cancer", "Stage IIIB Non-Small Cell Lung Cancer", "Stage IV Gallbladder Cancer", "Stage IV Non-Small Cell Lung Cancer", "Stage IV Pancreatic Cancer", "Unresectable Gallbladder Carcinoma", "Unresectable Pancreatic Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Recombinant EphB4-HSA Fusion Protein", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2015-09-03", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-06-25T17:23:30.584Z", "location_count": 2, "location_summary": "Los Angeles, California • Newport Beach, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02495896" }, { "nct_id": "NCT00023946", "title": "BMS-247550 in Treating Patients With Liver or Gallbladder Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Primary Cholangiocellular Carcinoma", "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Cholangiocarcinoma of the Extrahepatic Bile Duct", "Cholangiocarcinoma of the Gallbladder", "Localized Extrahepatic Bile Duct Cancer", "Localized Gallbladder Cancer", "Localized Resectable Adult Primary Liver Cancer", "Localized Unresectable Adult Primary Liver Cancer", "Recurrent Adult Primary Liver Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "ixabepilone", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2001-08", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2014-05-14", "last_synced_at": "2026-06-25T17:23:30.584Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023946" }, { "nct_id": "NCT06178588", "title": "Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Cholangiocarcinoma", "Metastatic Cholangiocarcinoma", "Recurrent Cholangiocarcinoma", "Stage III Hilar Cholangiocarcinoma AJCC v8", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Hilar Cholangiocarcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Sacituzumab Govitecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2024-02-01", "completion_date": "2026-11-01", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-06-25T17:23:30.584Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06178588" }, { "nct_id": "NCT01793168", "title": "Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rare Disorders", "Undiagnosed Disorders", "Disorders of Unknown Prevalence", "Cornelia De Lange Syndrome", "Prenatal Benign Hypophosphatasia", "Perinatal Lethal Hypophosphatasia", "Odontohypophosphatasia", "Adult Hypophosphatasia", "Childhood-onset Hypophosphatasia", "Infantile Hypophosphatasia", "Hypophosphatasia", "Kabuki Syndrome", "Bohring-Opitz Syndrome", "Narcolepsy Without Cataplexy", "Narcolepsy-cataplexy", "Hypersomnolence Disorder", "Idiopathic Hypersomnia Without Long Sleep Time", "Idiopathic Hypersomnia With Long Sleep Time", "Idiopathic Hypersomnia", "Kleine-Levin Syndrome", "Kawasaki Disease", "Leiomyosarcoma", "Leiomyosarcoma of the Corpus Uteri", "Leiomyosarcoma of the Cervix Uteri", "Leiomyosarcoma of Small Intestine", "Acquired Myasthenia Gravis", "Addison Disease", "Hyperacusis (Hyperacousis)", "Juvenile Myasthenia Gravis", "Transient Neonatal Myasthenia Gravis", "Williams Syndrome", "Lyme Disease", "Myasthenia Gravis", "Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome)", "Isolated Klippel-Feil Syndrome", "Frasier Syndrome", "Denys-Drash Syndrome", "Beckwith-Wiedemann Syndrome", "Emanuel Syndrome", "Isolated Aniridia", "Axenfeld-Rieger Syndrome", "Aniridia-intellectual Disability Syndrome", "Aniridia - Renal Agenesis - Psychomotor Retardation", "Aniridia - Ptosis - Intellectual Disability - Familial Obesity", "Aniridia - Cerebellar Ataxia - Intellectual Disability", "Aniridia - Absent Patella", "Aniridia", "Peters Anomaly - Cataract", "Peters Anomaly", "Potocki-Shaffer Syndrome", "Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11", "Silver-Russell Syndrome Due to Imprinting Defect of 11p15", "Silver-Russell Syndrome Due to 11p15 Microduplication", "Syndromic Aniridia", "WAGR Syndrome", "Wolf-Hirschhorn Syndrome", "4p16.3 Microduplication Syndrome", "4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome", "Autosomal Recessive Stickler Syndrome", "Stickler Syndrome Type 2", "Stickler Syndrome Type 1", "Stickler Syndrome", "Mucolipidosis Type 4", "X-linked Spinocerebellar Ataxia Type 4", "X-linked Spinocerebellar Ataxia Type 3", "X-linked Intellectual Disability - Ataxia - Apraxia", "X-linked Progressive Cerebellar Ataxia", "X-linked Non Progressive Cerebellar Ataxia", "X-linked Cerebellar Ataxia", "Vitamin B12 Deficiency Ataxia", "Toxic Exposure Ataxia", "Unclassified Autosomal Dominant Spinocerebellar Ataxia", "Thyroid Antibody Ataxia", "Sporadic Adult-onset Ataxia of Unknown Etiology", "Spinocerebellar Ataxia With Oculomotor Anomaly", "Spinocerebellar Ataxia With Epilepsy", "Spinocerebellar Ataxia With Axonal Neuropathy Type 2", "Spinocerebellar Ataxia Type 8", "Spinocerebellar Ataxia Type 7", "Spinocerebellar Ataxia Type 6", "Spinocerebellar Ataxia Type 5", "Spinocerebellar Ataxia Type 4", "Spinocerebellar Ataxia Type 37", "Spinocerebellar Ataxia Type 36", "Spinocerebellar Ataxia Type 35", "Spinocerebellar Ataxia Type 34", "Spinocerebellar Ataxia Type 32", "Spinocerebellar Ataxia Type 31", "Spinocerebellar Ataxia Type 30", "Spinocerebellar Ataxia Type 3", "Spinocerebellar Ataxia Type 29", "Spinocerebellar Ataxia Type 28", "Spinocerebellar Ataxia Type 27", "Spinocerebellar Ataxia Type 26", "Spinocerebellar Ataxia Type 25", "Spinocerebellar Ataxia Type 23", "Spinocerebellar Ataxia Type 22", "Spinocerebellar Ataxia Type 21", "Spinocerebellar Ataxia Type 20", "Spinocerebellar Ataxia Type 2", "Spinocerebellar Ataxia Type 19/22", "Spinocerebellar Ataxia Type 18", "Spinocerebellar Ataxia Type 17", "Spinocerebellar Ataxia Type 16", "Spinocerebellar Ataxia Type 15/16", "Spinocerebellar Ataxia Type 14", "Spinocerebellar Ataxia Type 13", "Spinocerebellar Ataxia Type 12", "Spinocerebellar Ataxia Type 11", "Spinocerebellar Ataxia Type 10", "Spinocerebellar Ataxia Type 1 With Axonal Neuropathy", "Spinocerebellar Ataxia Type 1", "Spinocerebellar Ataxia - Unknown", "Spinocerebellar Ataxia - Dysmorphism", "Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature", "Spasticity-ataxia-gait Anomalies Syndrome", "Spastic Ataxia With Congenital Miosis", "Spastic Ataxia - Corneal Dystrophy", "Spastic Ataxia", "Rare Hereditary Ataxia", "Rare Ataxia", "Recessive Mitochondrial Ataxia Syndrome", "Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature", "Posterior Column Ataxia - Retinitis Pigmentosa", "Post-Stroke Ataxia", "Post-Head Injury Ataxia", "Post Vaccination Ataxia", "Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract", "Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus", "Non-hereditary Degenerative Ataxia", "Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity", "Olivopontocerebellar Atrophy - Deafness", "NARP Syndrome", "Myoclonus - Cerebellar Ataxia - Deafness", "Multiple System Atrophy, Parkinsonian Type", "Multiple System Atrophy, Cerebellar Type", "Multiple System Atrophy", "Maternally-inherited Leigh Syndrome", "Machado-Joseph Disease Type 3", "Machado-Joseph Disease Type 2", "Machado-Joseph Disease Type 1", "Leigh Syndrome", "Late-onset Ataxia With Dementia", "Infection or Post Infection Ataxia", "GAD Ataxia", "Hereditary Episodic Ataxia", "Gliadin/Gluten Ataxia", "Friedreich Ataxia", "Fragile X-associated Tremor/Ataxia Syndrome", "Familial Paroxysmal Ataxia", "Exposure to Medications Ataxia", "Episodic Ataxia With Slurred Speech", "Episodic Ataxia Unknown Type", "Episodic Ataxia Type 7", "Episodic Ataxia Type 6", "Episodic Ataxia Type 5", "Episodic Ataxia Type 4", "Episodic Ataxia Type 3", "Episodic Ataxia Type 1", "Epilepsy and/or Ataxia With Myoclonus as Major Feature", "Early-onset Spastic Ataxia-neuropathy Syndrome", "Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity", "Early-onset Cerebellar Ataxia With Retained Tendon Reflexes", "Early-onset Ataxia With Dementia", "Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia", "Dilated Cardiomyopathy With Ataxia", "Cataract - Ataxia - Deafness", "Cerebellar Ataxia, Cayman Type", "Cerebellar Ataxia With Peripheral Neuropathy", "Cerebellar Ataxia - Hypogonadism", "Cerebellar Ataxia - Ectodermal Dysplasia", "Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss", "Brain Tumor Ataxia", "Brachydactyly - Nystagmus - Cerebellar Ataxia", "Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia", "Autosomal Recessive Syndromic Cerebellar Ataxia", "Autosomal Recessive Spastic Ataxia With Leukoencephalopathy", "Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay", "Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria", "Autosomal Recessive Spastic Ataxia", "Autosomal Recessive Metabolic Cerebellar Ataxia", "Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine", "Autosomal Recessive Ataxia, Beauce Type", "Autosomal Recessive Ataxia Due to Ubiquinone Deficiency", "Autosomal Recessive Ataxia Due to PEX10 Deficiency", "Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia", "Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency", "Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency", "Autosomal Recessive Congenital Cerebellar Ataxia", "Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome", "Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency", "Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency", "Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency", "Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome", "Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity", "Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency", "Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect", "Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion", "Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation", "Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness", "Autosomal Recessive Cerebellar Ataxia", "Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly", "Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation", "Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy", "Autosomal Dominant Spastic Ataxia Type 1", "Autosomal Dominant Spastic Ataxia", "Autosomal Dominant Optic Atrophy", "Ataxia-telangiectasia Variant", "Ataxia-telangiectasia", "Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy", "Autosomal Dominant Cerebellar Ataxia Type 4", "Autosomal Dominant Cerebellar Ataxia Type 3", "Autosomal Dominant Cerebellar Ataxia Type 2", "Autosomal Dominant Cerebellar Ataxia Type 1", "Autosomal Dominant Cerebellar Ataxia", "Ataxia-telangiectasia-like Disorder", "Ataxia With Vitamin E Deficiency", "Ataxia With Dementia", "Ataxia - Oculomotor Apraxia Type 1", "Ataxia - Other", "Ataxia - Genetic Diagnosis - Unknown", "Acquired Ataxia", "Adult-onset Autosomal Recessive Cerebellar Ataxia", "Alcohol Related Ataxia", "Multiple Endocrine Neoplasia", "Multiple Endocrine Neoplasia Type II", "Multiple Endocrine Neoplasia Type 1", "Multiple Endocrine Neoplasia Type 2", "Multiple Endocrine Neoplasia, Type IV", "Multiple Endocrine Neoplasia, Type 3", "Multiple Endocrine Neoplasia (MEN) Syndrome", "Multiple Endocrine Neoplasia Type 2B", "Multiple Endocrine Neoplasia Type 2A", "Atypical Hemolytic Uremic Syndrome", "Atypical HUS", "Wiedemann-Steiner Syndrome", "Breast Implant-Associated Anaplastic Large Cell Lymphoma", "Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA)", "Hemophagocytic Lymphohistiocytosis", "Behcet's Disease", "Alagille Syndrome", "Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD)", "Lowe Syndrome", "Pitt Hopkins Syndrome", "1p36 Deletion Syndrome", "Jansen Type Metaphyseal Chondrodysplasia", "Cockayne Syndrome", "Chronic Recurrent Multifocal Osteomyelitis", "CRMO", "Malan Syndrome", "Hereditary Sensory and Autonomic Neuropathy Type Ie", "VCP Disease", "Hypnic Jerking", "Sleep Myoclonus", "Mollaret Meningitis", "Recurrent Viral Meningitis", "CRB1", "Leber Congenital Amaurosis", "Retinitis Pigmentosa", "Rare Retinal Disorder", "KCNMA1-Channelopathy", "Primary Biliary Cirrhosis", "ZMYND11", "Transient Global Amnesia", "Glycogen Storage Disease", "Alstrom Syndrome", "White Sutton Syndrome", "DNM1", "EIEE31", "Myhre Syndrome", "Recurrent Respiratory Papillomatosis", "Laryngeal Papillomatosis", "Tracheal Papillomatosis", "Refsum Disease", "Nicolaides Baraitser Syndrome", "Leukodystrophy", "Tango2", "Cauda Equina Syndrome", "Rare Gastrointestinal Disorders", "Achalasia-Addisonian Syndrome", "Achalasia Cardia", "Achalasia Icrocephaly Syndrome", "Anal Fistula", "Congenital Sucrase-Isomaltase Deficiency", "Eosinophilic Gastroenteritis", "Idiopathic Gastroparesis", "Hirschsprung Disease", "Rare Inflammatory Bowel Disease", "Intestinal Pseudo-Obstruction", "Scleroderma", "Short Bowel Syndrome", "Sacral Agenesis", "Sacral Agenesis Syndrome", "Caudal Regression", "Scheuermann Disease", "SMC1A Truncated Mutations (Causing Loss of Gene Function)", "Cystinosis", "Juvenile Nephropathic Cystinosis", "Nephropathic Cystinosis", "Kennedy Disease", "Spinal Bulbar Muscular Atrophy", "Warburg Micro Syndrome", "Mucolipidoses", "Mitochondrial Diseases", "Mitochondrial Aminoacyl-tRNA Synthetases", "Mt-aaRS Disorders", "Hypertrophic Olivary Degeneration", "Non-Ketotic Hyperglycinemia", "Fish Odor Syndrome", "Halitosis", "Isolated Congenital Asplenia", "Lambert Eaton (LEMS)", "Biliary Atresia", "STAG1 Gene Mutation", "Coffin Lowry Syndrome", "Borjeson-Forssman-Lehman Syndrome", "Blau Syndrome", "Arginase 1 Deficiency", "HSPB8 Myopathy", "Beta-Mannosidosis", "TBX4 Syndrome", "DHDDS Gene Mutations", "MAND-MBD5-Associated Neurodevelopmental Disorder", "Constitutional Mismatch Repair Deficiency (CMMRD)", "SPATA5 Disorder", "SPATA5L1 Related Disorder", "Acrodysostosis", "Multi-systematic Smooth Muscle Dysfunction Syndrome", "CRELD1 (Cysteine Rich With EGF Like Domains 1)", "GNB1 Syndrome", "Pyruvate Dehydrogenase Complex Deficiency Disease", "Beta Mannosidosis", "Kbg Syndrome", "Labrune Syndrome", "Metachromatic Leukodystrophy (MLD)", "Moyamoya Disease", "OPHN1 Syndrome", "Oculopharyngeal Muscular Dystrophy (OPMD)", "TUBB3 Mutation", "WOREE (WWOX-related Epileptic Encephalopathy", "SCAR12", "Skraban-Deardorff Syndrome", "Hereditary Myopathy With Early Respiratory Failure" ], "interventions": [], "intervention_types": [], "sponsor": "Sanford Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20000, "start_date": "2010-07", "completion_date": "2100-12", "has_results": false, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-06-25T17:23:30.584Z", "location_count": 1, "location_summary": "Sioux Falls, South Dakota", "locations": [ { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01793168" } ] }